BiotechTube

SGT-501

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Catecholaminergic Polymorphic Ventricular Tachycardia

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Trial Timeline

Feb 23, 2026 → May 1, 2031

NCT ID
NCT07148089

About SGT-501

SGT-501 is a phase 1 stage product being developed by Solid Biosciences for Catecholaminergic Polymorphic Ventricular Tachycardia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07148089. Target conditions include Catecholaminergic Polymorphic Ventricular Tachycardia.

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07148089Phase 1Recruiting